目的：观察ＩＡＰ（异环磷酰胺加阿霉素加顺铂）方案治疗肺癌的疗效和毒副反应。方法：异环磷酰胺１．５～２．０ｇ／ｍ２，静滴，第１～５天，阿霉素４０ｍｇ／ｍ２，静注，第１天；顺铂５０ｍｇ，静注，第３～５天，或１００ｍｇ／ｍ２，静滴，第３天，联合治疗中晚期非小细胞肺癌３５例。结果：完全缓解７例，部分缓解１３例，稳定７例，恶化８例，有效率（ＣＲ＋ＰＲ）为５７．１％。中位缓解期５个月，中位生存期９个月。毒性反应达Ⅲ、Ⅳ度者，白细胞减少为６５．７％，呕吐为２０．０％，脱发为３７．１％。有１例发生出血性膀胱炎，３１．４％病例发生感染，其中２例死亡。结论：ＩＡＰ方案是目前治疗非小细胞肺癌疗效最好的方案之一，可列为首选方案，但其对血液系毒性作用大，应严格掌握化疗适应证及化疗中加强对症支持治疗 Objective: To observe the efficacy and side effects of IAP (ifosfamide plus adriamycin plus cisplatin) regimen in the treatment of lung cancer. Methods: ifosfamide 1.5 ~ 2.0g/m2, intravenous infusion, the first 1 ~ 5 days, doxorubicin 40mg/m2, intravenous injection, the first day; Cisplatin 50mg, intravenous injection, 3rd ~ 5th Day, or 100 mg/m2, intravenous infusion, on the third day, 35 patients with advanced non-small cell lung cancer were treated with combination therapy. Results: 7 cases were completely relieved, 13 cases were partially relieved, 7 cases were stable, and 8 cases deteriorated. The effective rate (CR+PR) was 57.1%. The median remission period was 5 months and the median survival period was 9 months. Toxicity in patients with grades III and IV resulted in a leucopenia of 65.7%, vomiting of 20.0%, and alopecia of 37.1%. Hemorrhagic cystitis occurred in 1 case, infection occurred in 31.4% of cases, and 2 of them died. Conclusion: IAP regimen is currently one of the best treatment options for NSCLC and can be listed as the first choice, but it has a great toxic effect on the blood system. It should strictly control the indications for chemotherapy and strengthen the symptomatic supportive therapy in chemotherapy.